Riociguat improves health-related quality of life for patients with pulmonary arterial hypertension: results from the phase 4 MOTION study

by Namita Sood, Alvaro Aranda, David Platt, Anneliese LaRose, Frank Kleinjung, Gerald O’Brien
Published 2019-02-01

Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial

by Manuel J. Richter, Barbara Stollfuß, Alexander Roitenberg, Frank Kleinjung, Valentin Graeff , Sabine Berghaus, Christian Müller, Hossein-Ardeschir Ghofrani
Published 2018-09-01

Distinguishing atrial fibrillation from sinus rhythm using commercial pulse detection systems: The non-interventional BAYathlon study

by Christian Müller, Ulf Hengstmann, Michael Fuchs, Martin Kirchner, Frank Kleinjung, Harald Mathis, Stephan Martin, Ingo Bläse, Stefan Perings
Published 2021-05-01

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study

by Gérald Simonneau, Hossein-Ardeschir Ghofrani, Paul A. Corris, Stephan Rosenkranz, Ekkehard Grünig, Jim White, Vallerie V. McLaughlin, David Langleben, Christian Meier, Dennis Busse, Frank Kleinjung, Raymond L. Benza
Published 2020-12-01